| Abstrakt: |
CYCLOSPORINE TRIALS in persons with insulin-dependent diabetes mellitus (IDDM) offer both good news and bad.The good news is that the results have cinched the role of autoimmune responses in the disease's pathophysiology, opening the way for better combined immunotherapies. The bad news is that the drug, at least as it is now being used, offers at most an extended honeymoon from insulin dependence. But when cyclosporine therapy is withdrawn, the honeymoon is over.In recent months, clinical investigators from around the world have been reporting the results of controlled trials of cyclosporine in patients with recent-onset IDDM. At such meetings as the 35th postgraduate course of the American Diabetes Association in Palm Desert, Calif, the Research and Clinical Frontiers of Diabetes meeting in St Louis, and the American Diabetes Association scientific session in Indianapolis, discussion of the results has centered on weighing the potential risks against the benefits."With |
